How to Read a Startup's Financial Projections

Can you trust a business that claims it will earn $300 million while its checkbook is actually empty? Performing a rigorous startup financial analysis is the only way to separate a true opportunity from a charismatic founder's fantasy. Most professionals get blinded by bold visions and ignore the massive gaps in the spreadsheets.

In the early days of Theranos, Elizabeth Holmes used a PowerPoint slide to claim the company had secured deals that would generate hundreds of millions in revenue. She convinced sophisticated investors that she was building the next Apple. This story proves that even the smartest people in the room often fail to verify the math behind the hype.

What is Financial Due Diligence?

Financial due diligence is the investigative process of auditing a company's historical performance, current health, and future potential before an investment or partnership. In the book Bad Blood, John Carreyrou describes how CFO Henry Mosley tried to perform this task at Theranos in 2006. Mosley realized that the high-flying revenue numbers didn't match the reality of a product that barely worked.

This concept is the bedrock of safe investing and business expansion. It requires looking past the founder's charisma to find the hard evidence supporting their claims. Without it, you aren't investing; you're gambling on someone's ability to tell a convincing story.

Identify Flaws in Startup Financial Analysis

Spot Hidden Traps in Revenue Forecasting

Startups almost always use what venture capitalists call a hockey-stick forecast. This is a graph where revenue stays flat for a short time and then magically shoots up in a perfectly straight line. Theranos showed investors a slide deck listing six deals with five companies that would supposedly generate up to $300 million in eighteen months.

Smart analysts ignore the angle of the line and look for the specific customer names attached to it. If the founder claims those names are confidential, it's usually because the deals don't exist yet. The presence of $1.5 billion in potential revenue on a slide doesn't pay the bills unless there are signed contracts in a drawer somewhere.

Challenge the Logic of Venture Capital Models

Charisma can't fix a broken business model, but it can certainly hide one. Venture capital due diligence requires you to verify if the startup's technology can actually produce the results claimed in the financial model. Henry Mosley became suspicious when he learned that Theranos demos were using pre-recorded results rather than real-time data.

When the technology is a sham, the financial projections are purely decorative. You must ask the technical team if the product is capable of the high-throughput performance the sales team is promising. If the engineers are stressed and the sales deck is sunny, the numbers are probably inflated.

Demand the Real Paper Trail

Founders often hide behind the phrase "legal review" when asked for documentation. When Mosley asked to see the pharmaceutical contracts supporting the $300 million projection, he was told they were being reviewed by lawyers. This is a classic stall tactic used to prevent investors from seeing that a deal is non-binding or non-existent.

McKinsey research suggests that many failed partnerships occur because companies ignore red flags during this phase. If a startup won't show you a signed agreement, assume the revenue is zero. A real business partnership is backed by paper, not just a promise made during a lunch meeting at a coffee shop.

Real-World Examples

When Walgreens executives met with Theranos in 2010, they were presented with a list of 192 different blood tests the technology could supposedly handle. They were so excited about the "Project Beta" pilot that they committed to a $50 million prepurchase of cartridges and a $25 million loan. They prioritized the fear of missing out over basic verification of the technology.

Safeway also fell into this trap under CEO Steve Burd. The grocery giant spent $350 million remodeling its stores to build "wellness centers" for Theranos. Burd was so in thrall to Holmes that he allowed her to miss every single deadline. Safeway eventually lost its entire investment because the board and leadership failed to verify the science before spending the cash.

Verify the Numbers Before You Sign

1. Confirm the existence of every contract. Ask for the physical documents and verify that they are binding and executed, rather than just letters of intent. Do not accept "legal review" as an excuse for withholding these files.

2. Call the listed customers directly. Reach out to the companies the startup claims to be working with to verify the scope of their pilot programs. Ask specifically about the results of any validation studies or initial testing phases.

3. Match the bank statements to the claims. Review the company's actual cash flow for the last six months to see if any real revenue is coming in. If they claim a major deal but have no incoming wire transfers, the projections are likely fiction.

Where Spreadsheet Logic Falls Short

Financial due diligence often fails because it assumes that the people providing the data are acting in good faith. In a high-stakes startup environment, founders are often encouraged to "fake it 'til you make it." This mentality can lead to the outright fabrication of data and results, which no spreadsheet can detect.

Critics also argue that early-stage investing is more about the team than the math. However, the Theranos story shows that an all-star board of directors doesn't guarantee a solid business. Even legendary figures like George Shultz and Henry Kissinger were fooled because they focused on the founder's vision instead of the technical reality. Expert names on a letterhead are never a substitute for an audit of the actual lab performance.

Theranos secured a $9 billion valuation by convincing people that a converted glue-dispensing robot was a medical revolution. Real growth depends on a product that survives independent testing and delivers consistent, accurate results. Walk away from any deal where the founder prioritizes secrecy over showing you the physical proof of their progress.